February 03, 2012 | AdenoONE™ makes working with adenovirus a standard procedure 

Adenovirus vector cloning and production still remain tricky with rather low yields and limited success. The brand new AdenoONE™ line of support kits turns cloning & production into an easy to schedule project step of less than 4 weeks. AdenoONE™ comprises 2 discrete kits: AdenONE™ Cloning Kit and AdenoONE™ Purification Kit. The latter allows for reliable purification within just 20 minutes. Soon will SIRION BIOTECH, also referred to as Munich’s “Cell Competence Center”, launch the AdenoONE™ Purification Kit in vivo.

Press release in English

October 24, 2011 | InSphero AG and SIRION BIOTECH GmbH announce Development & Marketing cooperation on 3D-based cell models

InSphero AG and SIRION BIOTECH GmbH, two privately-held biotech com-panies based in Zurich and Martinsried near Munich, respectively, announced today an agreement allowing for a close cooperation on the development and the promotion of most innovative cell models in the form of three-dimensional (3D) microtissues.

Press release in English

JUNE 24, 2010 | TET Systems and SIRION BIOTECH GmbH sign a commercial license agreement

TET Systems (TET) and SIRION BIOTECH GmbH, two privately-held, German biotech companies based in Heidelberg and Martinsried near Munich, respectively, announced today that they have signed a commercial license agreement. Under the terms of the agreement, SIRION BIOTECH offers customized services to its clients using the Tet Technology to generate cell lines and to generate and manufacture recombinant viral vector products.

Press release in English
Press release in German

MARCH 25, 2010 | Helmholtz Zentrum München and SIRION BIOTECH Initiate Research Cooperation to Develop New Anti-Cancer Gene Therapy Approach Using Lentiviral Vectors

Helmholtz Zentrum München has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

Press release in English
Press release in German

Jan 2010 | SIRION BIOTECH and Sigma-Aldrich entered into a service agreement

under which SIRION BIOTECH provides custom shRNA knockdown cell lines, utilizing validated The RNAi Consortium (TRC) shRNA RNAi libraries from Sigma Life Science. First of all the offer is limited to the German research community.

Jan 2010 | SIRION BIOTECH successfully completes a test phase with more than 80 test sites for its new product TransMAX, an enhancer of adenovirus uptake, and launches TransMAX

The test customers detected up to 50 fold enhanced expression rates depending on the cell type. In addition, TransMAX has been shown to now enable gene transfer to human dendritic cells, mouse embryonic stem cell or skeletal muscle cells having a wide impact on the corresponding scientific areas.

Oct 2009 | SIRION BIOTECH together with Helmholtz Zentrum Munich (HGMU) receives funding from BMWi for finding new therapeutic approaches in leukemia

In the two years cooperation project funded with approx. 300 tEUR SIRION BIOTECH will facilitate viral delivery of siRNAs to hematopoietic cells which HGMU will use for target validation in leukemia research.